Table.3 Results of the regression analyses
From: Variables affecting pricing of orphan drugs: the Italian case
Dependent variable: Log cost | ||||||
|---|---|---|---|---|---|---|
(1) | (2) | (3) | (4) | (5) | (6) | |
Prevalence | − 0.582** (− 1.122, − 0.041) | − 0.526* (− 1.101, 0.049) | 0.829* (− 0.073, 1.731) | 1.197** (0.185, 2.210) | ||
RCT | − 0.176 (− 0.739, 0.387) | 0.141 (− 0.466, 0.748) | 1.029*** (0.301, 1.758) | 0.779* (− 0.002, 1.561) | ||
ASMR | − 0.338** (− 0.665, − 0.011) | − 0.287 (− 0.625, 0.052) | − 0.225 (− 0.530, 0.080) | − 0.203 (− 0.533, 0.127) | ||
ATC l | 0.091 (− 0.685, 0.867) | |||||
Class H of eligibility | − 0.205 (− 0.955, 0.545) | |||||
2015 | 1.468** (0.341, 2.595) | |||||
2016 | 0.908 (− 0.187, 2.004) | |||||
2017 | 1.376*** (0.399, 2.354) | |||||
2018 | 1.110** (0.097, 2.124) | |||||
2019 | 0.888 (− 0.160, 1.937) | |||||
Prevalence * RCT | − 2.016*** (− 3.118, − 0.915) | − 2.187*** (− 3.338, − 1.037) | ||||
Constant | 11.554*** (11.168, 11.939) | 11.430*** (10.976, 11.884) | 12.582*** (11.277, 13.886) | 12.653*** (11.260, 14.047) | 11.936*** (10.629, 13.244) | 10.885*** (9.236, 12.534) |
Observations | 63 | 60 | 55 | 52 | 52 | 52 |
R2 | 0.068 | 0.006 | 0.072 | 0.123 | 0.312 | 0.449 |